Berlin-headquartered biotech firm Atai Life Sciences, which specialises in psychedelic treatments for mental health disorders, has raised $157m amid the global race to commercialise psychedelics.
The company’s Series D raise follows a $125m funding round in November last year and comes as it’s rumoured to be preparing an IPO. The valuation on Wednesday was not disclosed, but Bloomberg reported that it was $2bn.
“We continue on our mission challenging the current way mental health conditions are treated,” said Florian Brand, CEO and cofounder of Atai. “We have become better equipped than ever to accelerate the development of more efficacious treatments.”
The investors in Atai’s $157m Series D include:
- Thiel Capital
- Apeirion Investment Group — the family office of Atai’s founder, Christian Angermayer. Sifted chatted with Angermayer about Atai and his other investments earlier this year.
- Woodline Partners LP
- Fearless Ventures
- Falcon Edge Capital
- Pura Vida Pro LLC
- Catalio Capital Management
- Subversive Capital, Michael Auerbach
- Highline Capital